Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients

Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients

(1)<b> </b>Background: The phase 2 Regorafenib in Relapsed Glioblastoma (REGOMA) trial indicated a survival benefit for patients with first recurrence of a glioblastoma when treated with the multikinase inhibitor regorafenib (REG) instead of lomustine. The aim of this retrospective study...

Full description

Bibliographic Details
Main Authors: Pia S. Zeiner, Martina Kinzig, Iris Divé, Gabriele D. Maurer, Katharina Filipski, Patrick N. Harter, Christian Senft, Oliver Bähr, Elke Hattingen, Joachim P. Steinbach, Fritz Sörgel, Martin Voss, Eike Steidl, Michael W. Ronellenfitsch
Format: Article
Language:English
Published: MDPI AG 2019-11-01
Series:Journal of Clinical Medicine
Subjects:
malignant glioma
glioblastoma
regorafenib
regorafenib csf concentration
mri patterns of gliomas
Online Access:https://www.mdpi.com/2077-0383/8/12/2031

Internet

https://www.mdpi.com/2077-0383/8/12/2031

Similar Items